RARE: Ultragenyx Pharmaceutical Inc

RARE新闻

• 16:28 IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
• 14:15 Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
• 15:43 Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
• 23:32 Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• 15:30 Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
• 02:20 Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• 16:00 RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
• 22:00 Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
• 21:10 Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
• 14:00 Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
• 14:00 Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
• 12:47 Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts (NASDAQ:RARE)
• 11:10 Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
• 16:44 RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
• 16:15 Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND